Multiple Myeloma Clinical Trial
Now Enrolling: K36-MMSET-001 Clinical Trial for Relapsed/Refractory Multiple Myeloma
We are actively enrolling patients in the US, Canada, France & Spain in our ongoing Phase 1 clinical trial evaluating KTX-1001, a selective NSD2 inhibitor, in combination with standard of care and novel iMiDs for relapsed/refractory multiple myeloma (rrMM).
Dose expansion cohorts are now open.
To learn more about the study and participating clinical centers, please visit:
www.clinicaltrials.gov (NCT05651932).
Prostate Cancer Clinical Trial
Now Selecting Sites: STRIKE-001 Phase 1 Clinical Trial in the U.S.
We are initiating our first-in-human Phase 1 clinical study (STRIKE-001) evaluating KTX-2001, a selective NSD2 inhibitor, as monotherapy and in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
​
Enrollment will soon open across the United States.
To learn more about the study and participating clinical centers, please visit: www.clinicaltrials.gov (NCT07103018).